APUS vs NOC · $2.4M cap vs P/E 17, rev $20.76B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Northrop Grumman Corporation (NOC) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
APUS does not have a complete income-statement cache yet.
Latest reported NOC revenue for 2026-06-30 was $20.76B. Net income was $1.97B. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
APUS currently screens at market cap $2.4M. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Not investment advice. Open the APUS and NOC stock pages for the full models.
Not investment advice.